Perioperative Liraglutide to Prevent Postoperative Delirium in Elderly Patients with Type 2 Diabetes Undergoing Cardiac Surgery

What this Trial Is About

Researchers are evaluating whether using liraglutide around the time of surgery can prevent postoperative delirium in elderly patients aged 60 and above with Type 2 diabetes undergoing cardiac surgery. Delirium is a common and serious complication after such surgeries, linked to worse outcomes including longer hospital stays and lasting cognitive issues. The study is a randomized controlled trial aimed at understanding if liraglutide can reduce this risk by reducing neuroinflammation. Participants will receive either liraglutide or a placebo through subcutaneous injections. The liraglutide dosing starts with 0.6 mg the day before surgery, followed by 1.8 mg after anesthesia induction on the surgery day, then 0.6 mg daily for the next three days. The placebo group receives injections matching the liraglutide schedule. This treatment is given during the perioperative period in a double-blind setup to assess effects on delirium prevention and other health outcomes. During the study, patients will be closely monitored from one day before surgery through seven days post-surgery for delirium incidence and severity. Cognitive function, anxiety, depression, heart function, ICU stay length, mechanical ventilation time, and hospital stay duration will be assessed at multiple points up to one year after surgery. Blood samples will be taken at set intervals to measure markers related to brain injury, inflammation, and cardiac function. Safety and adverse events will also be tracked throughout the study period.

Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery